Monday 4 March | |
Ascent Resources PLC | GM re bonus issue of preference shares |
JPMorgan Emerging Europe, Middle East & Africa Securities PLC | AGM |
Lexington Gold Ltd | AGM |
Tuesday 5 March | |
Ajax Resources PLC | GM re extension of investment mandate |
Beowulf Mining PLC | GM re capital raise |
CC Japan Income & Growth Trust PLC | AGM |
Driver Group PLC | AGM |
Edinburgh Worldwide Investment Trust PLC | AGM |
Jersey Electricity PLC | AGM |
Wednesday 6 March | |
Ecofin Global Utilities & Infrastructure Trust PLC | AGM |
Mila Resources PLC | AGM |
Paragon Banking Group PLC | AGM |
Thursday 7 March | |
Asia Strategic Holdings Ltd | AGM |
CT UK Capital & Income Investment Trust PLC | AGM |
Henderson Opportunities Trust PLC | AGM |
XPS Pensions Group PLC | GM re directors' remuneration policy 2024 |
Friday 8 March | |
Allergy Therapeutics PLC | AGM |
All Things Considered Group PLC | AGM |
Chenavari Toro Income Fund Ltd | AGM |
Neo Energy Metals PLC | AGM |
Schroder UK Mid Cap Fund PLC | AGM |
Silverwood Brands PLC | GM re proposed share capital reduction |
Comments and questions to newsroom@alliancenews.com | |
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional. | |
Copyright 2024 Alliance News Ltd. All Rights Reserved. |
IN BRIEF: Allergy Therapeutics extends cash runway until end of 2023
Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.
Read more